To evaluate the effects of SSTR antagonists in this context, we developed a high-fat fed (HFF) low dose streptozotocin (STZ)-induced rodent model of late-stage T2D, adapted from a previously existing model (Srinivasan et al., 2005) due to its similarities to the T2D clinical phenotype, to better characterize glucagon dysregulation in T2D and to assess if SSTR2 antagonists have therapeutic potential for hypoglycemia prevention in this form of diabetes. This evidence concerns the gene SSTR2 and Hypoglycemia.